Symptom Management: Cancer Pain -...
Transcript of Symptom Management: Cancer Pain -...
2/19/2016
1
Symptom Management: Cancer Pain
Kelley Blake RN, MSN, OCN, AOCNS
Valley Medical Center
Objectives
• Explore cancer pain
• Discuss barriers
• Manage pain in special populations
• Discuss pain treatment therapies
Pain
Is whatever the person says it is
Existing whenever he or she says it does
Pain
The International Association for the Study of Pain states:
Pain is defined as an unpleasant, multidimensional sensory and emotional experience associated with actual or potential tissue damage or described in relation to such damage
2/19/2016
2
Cancer Pain
• It is estimated that 90% of cancer pain can be controlled with currently available medications
Characteristics of Pain
• Acute pain
– Less than 6 mo.
– Pain behaviors exhibited
• Chronic pain
– Longer than 3 mo.
– Fatigue/depression common
Characteristics of Pain
• Breakthrough pain
– Transient increase over background pain
– Rapid onset
– Severe intensity
– Self-limiting
– Average duration 30 minutes
• Refractory/ Intractable pain
– Inadequately controlled despite aggressive measures
Characteristics of Cancer Pain
• Acute and chronic
• Direct tumor involvement
• Diagnostic/ therapeutic procedures
• Cancer treatment
• May trigger fear
– Cancer progression
– Recurrence
• Worsens with
– Anxiety
– Hopelessness
– Depression
2/19/2016
3
Types of Pain: Nociceptive Pain
• Somatic pain
– Bone/joint/ connective tissue
– Sharp/throbbing/ pressure
– Well localized
• Visceral pain
– Distension/ compression
– Diffuse/aching/ cramping
– Poorly localized
Types of Pain: Neuropathic Pain
• Peripheral neuropathic pain
– Peripheral nerve injury
– Numbness/tingling
• Centrally mediated pain
– Radiating/shooting
– Burning/aching
• Sympathetically maintained pain
– Centrally generated
– Autonomic dysregulation
– Complex regional pain syndrome
Physiology of Pain
• Transduction
– stimulus
• Transmission
– Message relay
• Perception
– Pain experience
• Modulation
– Release of neuromediators
Risk Factors of Cancer Pain
Disease Related
• Type of cancer
• Bone metastases
• Visceral pain
• Nerve compression/injury
Treatment Related
• Chemotherapy
• Radiation therapy
• Chronic pain related to cancer surgery
2/19/2016
4
Barriers: Patient-Related Factors
Reluctance to report pain
Concern about distracting physicians from treatment of underlying disease
Fear that pain means disease is worse
Lack of knowledge about principles of basic pain management
Concern about not being a “good” patient
Reluctance to take pain medications
Fear of addiction/being thought of as an addict
Worries about unmanageable side effects
Concern about becoming tolerant to pain medications
Poor adherence to the prescribed analgesic regimen
Financial barriers
Barriers: Provider-Related Factors
Probable Problems
Inadequate knowledge of pain management
Poor assessment of pain
Concern about regulation of controlled substances
Fear of patient addiction
Concern about side effects of analgesics
Concern about patients becoming tolerant to analgesics
Possible Solutions
Appropriate pain management education
Nurse/patient advocacy Persistence/not pushy
Communication What is the plan?
Pain clinic referral
CAM referrals
Manage side effects
Barriers: Health Care System-Related
• Low priority given to cancer pain treatment
• Inadequate reimbursement for pain assessment and treatment
• The most appropriate treatment may not be reimbursed or may be too costly for patients and families
• Restrictive regulation of controlled substances
• Problems of availability of treatment or access to it
• Opioids unavailable in the patient’s pharmacy
• Unaffordable medication
Special Populations
• Older adult
– Polypharmacy
– Increased sensitivity
– Appropriate pain scale
– Confusion/poor vision
– Home supervision
– Cost
• Pediatric
– Developmental age
– Appropriate pain scale
– Dose by weight
2/19/2016
5
Polypharmacy
Risks and Complications
Adverse drug reaction increases with number of drugs
Duplication of therapy
Drug-drug interactions
Drug-disease interactions
Adherence
Cost
Polypharmacy
Management Questions
Indications?
Desired effect?
Nonspecific symptoms?
Dose?
Drug-drug interactions?
Antineoplastic treatment interference?
Drug-tumor interactions?
Adherence?
Untreated conditions?
Special Populations: Patients Addicted to Drugs
• The uncomplicated patient
– Routine
• The patient with comorbid psychiatric and coping difficulties
– Structure
– Psychotherapy
• The addicted patient
– Maximum structure
– Limited supply
– Long-acting opioids of low street value
– Recovery program
– Psychotherapy
Analgesics
Goals of Therapy
To reduce the effect of noxious stimuli caused by thermal, chemical, or mechanical injury that elicits pain
To improve quality of life
Types of Analgesics
• Nonopioid analgesics
• Opioids
• Adjuvants
2/19/2016
6
Assessment
Identify Risk for Pain
Pain type
History of past/current analgesia and effectiveness
Side effects from previous regimens
Physical exam
Current medications
Diagnostics
Cultural/ethnic background
Cancer Pain Assessment
• Assess for all types of acute and chronic pain
• Reassure that most cancer pain can be relieved safely, quickly, and effectively
• Basic and ongoing professional education for clinicians on effective cancer pain assessment
Pain Management
Neuropathic Pain
• Trial antidepressant
• Trial anticonvulsant
• Consider topical
• Pain specialist
Mild Pain (Level 1-3)
• NSAID or acetaminophen
• Short-acting opioid
• Bowel regimen
• Treat side effects
• Nonopioid analgesics
• Psychosocial support
• Education
Pain Management
Moderate Pain (Level 4-6)
• Titrate short-acting opioid
• Bowel regimen
• Treat side effects
• Nonopioid analgesics
• Psychosocial support
• Education
Severe Pain (Level 7-10)
• Titrate short-acting opioid
• Bowel regimen
• Treat side effects
• Nonopioid analgesics
• Psychosocial support
• Education
• Reassess and modify
• Long-acting opioid
• Specific pain problems
• Specialty consultation
2/19/2016
7
Pharmacological Therapies: using WHO stepladder approach
Step 1: Non-opioids +/- Adjuvant
Step 2: Opioids for mild to moderate pain +/- Non-opioids
+/- Adjuvants Step 3: Opioids for
moderate to severe pain +/- Non-opioids
+/- Adjuvants
Acetaminophen: Step 1
• To reduce pain and fever
• Treatment of mild to moderate pain
• May cause liver damage
• Do not exceed 4g/24 hours
Anti-Inflammatory Agents: Step 1
To reduce inflammation and pain
Treatment of mild to moderate pain
Symptom management
Boney metastases
Addition of NSAIDs can reduce opioid dose requirements
Anti-Inflammatory Agents: Step 1
Commonly Used NSAIDs in Cancer
• Propionic Acids – Ibuprofen
• Acetic Acids – Ketorolac
• Oxicam – Piroxicam
• Salicylates – Aspirin
• Cyclo-oxygenase-2 Selective Inhibitor – Celecoxib
2/19/2016
8
Anti-Inflammatory Agents: Step 1
Corticosteroids Used in the Treatment of Cancer
• Short-Acting (8-12 hr) – Hydrocortisone
• Intermediate-Acting (12-36 hr) – Prednisone
• Long-Acting – Dexamethasone
Anti-Inflammatory Agents: Step 1
Potential adverse effects
• Renal toxicity
• Cardiac toxicity
Risk factors for NSAID toxicities
• Age greater than 60
• Thrombocytopenia
• Renal insufficiency
• Comorbid disease – Multiple myeloma
Anti-Inflammatory Agents: Step 1
Adverse Effects of NSAIDs Related to Cancer
• Central Nervous System
• Cardiovascular
• Hematologic
• Platelet aggression
Adverse Effects of Corticosteroids Related to Cancer
• Psychiatric disturbances
• Immunosuppression
Opioids: Step 2-3
▫Most appropriate dose controls pain through 24 hours
▫Long-acting and breakthrough options with constant pain
▫Effective titration
Breakthrough dose
10%--20% of long-acting dose
2/19/2016
9
Opioids: Step 2-3
• Tolerance: when taken regularly
• Physical dependence: all patients when taken regularly
• Psychological dependence: ADDICTION
Opioids: Step 2-3
Potential Adverse Effects
Dependence
Drug interactions
Abnormalities in absorption
Opioid Withdrawal
• Nausea/vomiting/diarrhea
• Tachycardia
• Chills
• Anxiety/paranoia
• insomnia
Opioids: Step 2-3
Adverse Effects of Opioids
Gastrointestinal
Respiratory
Central nervous system
Potential Adverse Effects Caused by Compromised Organ Systems
Hepatic insufficiency
Central nervous system
Respiratory
Opioids: Managing Adverse Effects
• Antiemetic
• Prophylaxis for Constipation
• V/S
• Pupil size
• Sedation/RR
• Neuro
• Safety
2/19/2016
10
Opioids: Managing Constipation
• Universal side effect
• Prophylaxis
– Stool softener
– Bowel stimulant
• Decrease intestinal secretion/peristalsis
• Increase muscle tone
• Increase segmental contractions of bowel
• Decrease stool volume/ frequency
• Increase water/ electrolyte absorption
Adjuvants: Anxiolytics/Sedative-Hypnotics
To reduce pain associated with anxiety
Benzodiazepines
Other medications
Selective serotonin reuptake
inhibitors
Serotonin norepinephrine reuptake inhibitors
Adjuvants: Anxiolytics/Sedative-Hypnotics
Potential Adverse Effects
• CNS effects
• Delirium
• Respiratory suppression
Drug Interactions
Alcohol
Inhibitors or inducers of hepatic enzyme CYP3A4
Adjuvants: Antidepressants
• To treat depression associated with chronic pain
• As adjuvant pharmacologic pain management in pain conditions
– Postherpetic neuralgia
2/19/2016
11
Adjuvants: Antidepressants
Common Antidepressants
• Tricyclic Antidepressants
• Serotonin Reuptake Inhibitors
• Mixed-Action Agents
Potential Adverse Effects
• Drug-drug interactions
• Dietary restrictions
Adjuvants: Anticonvulsants
As adjuvant pharmacologic therapy for pain with neurologic cause
Peripheral neuropathy
• Valproic acid
• Lamotrigine
Adjuvants: Anticonvulsants
Patients at risk for neurologic pain
Chemotherapy Paclitaxel
Vincristine
Oxaliplatin
Adverse Effects
• Nausea
• Sedation
• Irritability
• Headaches
• Depression
• Liver failure
Adjuvants: Miscellaneous Interventions
Pharmaceuticals for Bone Metastases
• Radionuclides
• Bisphosphonates
Intraspinal Analgesia
Epidural
Intrathecal implantable pump
Bone metastases
Reduce bulky tumors
Radiation Therapy
2/19/2016
12
Adjuvants: Miscellaneous Interventions
Interventional/Surgical Strategies
• Nerve blocks
• Neurostimulation
• Percutaneous kyphoplasty
• Debulking
Nonpharmacologic Interventions
CAM
Patient/family education
Interventions to Increase Comfort
Complementary and Integrative Modalities
• Alternative medical systems
• Energy therapies
• Exercise therapies
• Manipulative and body-based methods
Mind-body interventions
Nutritional therapeutics
Pharmacologic and biologic treatments
Spiritual therapies
Cannabis
Has been used for medicinal purposes for thousands of years
Illegal in the US, however legal in WA and other states
Not approved by FDA for medical treatment
Points to remember
• Treat the underlying cause of pain
• Administer around the clock
• Manage breakthrough pain
• Oral preferred route
• Minimize side effects
• Review patient instructions
2/19/2016
13
References
• American Pain Society. (2005). Guideline for the management of cancer pain in adults and children. Glenview, IL.
• Balducci, L., Goetz-Parten, D., & Steinman, M. A. (2013). Polypharmacy and the management of the older cancer patient, Annals of Oncology 23 (Sup 7): vii36-vii40, doi: 10.1093/annonc/mdt266. Retrieved from http://annonc.oxfordjournals.org/ on July 3, 2015.
• Brant, J., Visich, K.L., Sterling, B., & Irwin, M. (2014). Pain. In M. Irsin & L. Johnson (Eds.). Putting evidence into practice: P pocket guide to cancer symptom management (pp. 177-184). Pittsburgh, PA: Oncology Nursing Society.
• Brant J.M., & Stinger, L.H. (2015). Pain. In C.G Brouwn (Ed.). A guide to oncology symptom management. 2nd ed., pp. 505-526). Pittsburgh, PA: Oncology Nursing Society.
References
• Itano, J. K., editor (2016). ONS Core curriculum for oncology nursing, 5th ed., Elsevier, St. Louis, Missouri, pp. 287-426.
• National Comprehensive Cancer Network. (2015). NCCN Clinical Practice Guidelines in Oncology: Adult cancer pain [v.2.2015]. Retrieved from http://www.nccn.ort/professionals/physician_gls/pdf/pain.pdf
• Pain pdq & CAM pdq, National Cancer Institute Office of Cancer Complimentary and Alternative Medicin (NCI OCCAM, 2015). http://www.cancer.gov
• Treating cancer pain in patients addicted to drugs, (Feb 2007). The journal of supportive oncology. Vol 5:no 2. pp. 63-64. www.SupportiveOncology.net